Bullous pemphigoid and the pembrolizumab conundrum
Pembrolizumab is an immune checkpoint inhibitor that is gaining widespread use as an immunotherapy for various cancers. With its growing application, a range of immune-related adverse events are being more frequently recognized. Pruritus, lichenoid reaction and eczema are known dermatological advers...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wolters Kluwer Medknow Publications
2026-01-01
|
| Seri Bilgileri: | Journal of the Egyptian Women’s Dermatologic Society |
| Konular: | |
| Online Erişim: | https://journals.lww.com/10.4103/jewd.jewd_38_25 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|